GLP-1 receptor agonist market seen reaching $72.3B by 2033

By AI, Created 5:05 PM UTC, May 18, 2026, /AGP/ – A new market report projects the global GLP-1 receptor agonist market will grow from $31.71 billion in 2026 to $72.33 billion by 2033, driven by demand across diabetes, obesity and other applications. The report highlights major players including Eli Lilly, Sanofi and Novo Nordisk, and points to expanding opportunities in oral and parenteral treatments.

Why it matters: - The GLP-1 receptor agonist market is projected to nearly double by 2033, signaling strong demand in one of the fastest-growing drug categories. - The forecast points to sustained commercial opportunities for drugmakers, investors and suppliers across diabetes, obesity and liver-related indications. - The report estimates the market will reach $31.71 billion in 2026 and $72.33 billion by 2033, a 12.5% compound annual growth rate.

What happened: - Coherent Market Insights released a report titled “GLP-1 Receptor Agonist Market 2026 Forecast to 2033.” - The report covers global, regional and country-level market outlooks. - The report highlights Eli Lilly and Company, Sanofi, Novo Nordisk A/S, AstraZeneca, Perrigo Company PLC, 3M Company, Bausch Health, Taro Pharmaceutical Industries, Novan Inc., Serum Institute of India Pvt. Ltd., Orgenesis, Verrica Pharmaceuticals, AbbVie Inc., Lee’s Pharmaceutical Holdings Ltd, Cassiopea and Glenmark Pharmaceuticals. - The report includes a sample request link: Request a sample of the analysis report.

The details: - The market analysis covers drug class, route of administration, application and distribution channel. - Drug classes in the report include exenatide, liraglutide, dulaglutide, lixisenatide, albiglutide and semaglutide. - Routes of administration include parenteral and oral. - Applications include type 2 diabetes mellitus, obesity, liver cirrhosis, non-alcoholic steatohepatitis and others. - Distribution channels include hospital pharmacies, retail pharmacies and online pharmacies. - Regional coverage includes North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and the Middle East & Africa. - The methodology combines primary research, including interviews with industry stakeholders, and secondary sources such as annual reports, white papers and government publications. - The report says its approach blends qualitative and quantitative methods to support forecasts and business intelligence.

Between the lines: - The report frames GLP-1 drugs as a category with broad use cases beyond diabetes, especially obesity treatment. - The inclusion of oral and parenteral formats suggests competition is expanding beyond injectable therapies. - The long list of players shows a crowded field where scale, pipeline depth and distribution access may matter as much as product approval.

What’s next: - The report says executives, investors and decision-makers can use the findings to assess demand shifts, technology trends and investment opportunities. - The publication also points to future growth prospects, regulatory frameworks and technological innovation as factors shaping the sector. - Coherent Market Insights offers report access and a discounted purchase link: Access the discounted report.

The bottom line: - GLP-1 receptor agonists are moving from a niche diabetes category into a broader growth market, with obesity and oral formulations likely to drive much of the next wave of demand.